All In Biotech

Drug Trial Radar · NCT07884747

Hypernatremia Fluid Therapy in Childhood Diarrhoea

Oral Versus Intravenous Fluid Therapy for Hypernatremic Dehydration in Children Under Five With Diarrhoea: A Randomized, Controlled, Non-Inferiority Trial

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

268

Planned (sponsor's estimate)

Start

Jan 13, 2026

Primary completion

Dec 12, 2028

Study completion Dec 31, 2028

Sponsor

Sponsor type
Academic, hospital or other
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 day, up to 59 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hypernatremic dehydration is a life-threatening condition, particularly in children under two years of age, with mortality rates reaching up to as high as 19%. Infants are highly susceptible due to immature renal function, increased insensible water loss, and limited ability to express thirst. Severe hypernatremia can cause cerebral complications such as brain shrinkage, haemorrhage, seizures, paralysis, and encephalopathy. Furthermore, rapid or improperly managed fluid and electrolyte treatment can increase the risk of cerebral oedema and death. Although gradual sodium correction is widely recommended for hypernatremia, the optimal rate, route, and type of fluid therapy remain uncertain. Current treatment practices vary and no standardized protocol has been validated in randomized clinical trials for young children. This gap contributes to persistently high mortality and neurological morbidity. The goal of this clinical trial is to determine whether oral rehydration therapy is non-inferior to intravenous fluid therapy in the management of hypernatremic dehydration among children under five years of age with diarrhoea. The main questions it aims to answer are: Does oral rehydration therapy result in mortality rates comparable to those of intravenous fluid therapy among children with hypernatremic dehydration? Does oral rehydration therapy achieve safe correction of serum sodium levels and comparable neurological and clinical outcomes relative to intravenous fluid therapy? Researchers will compare oral rehydration therapy using oral rehydration salt (ORS) solution with intravenous fluid therapy using half-strength acetate in 5% dextrose to determine whether oral therapy is non-inferior to intravenous therapy in reducing mortality and improving clinical outcomes. Total 268 participants will: Be randomly assigned to 1:1 to receive either oral rehydration therapy or intravenous fluid therapy. Receive standardized fluid volumes calculated according to paediatric treatment protocols. Undergo clinical assessments and laboratory investigations, including serial serum sodium measurements, during hospitalization. Be monitored for adverse outcomes, including convulsions, fluid overload, and renal impairment. Have neurological status assessed using the Glasgow Coma Scale (GCS) on admission and at discharge. Attend follow-up assessments at 1 month and 6 months after discharge for neurodevelopmental evaluation using the Denver Developmental Screening Test II.

Conditions

  • Hypernatremia
  • Acute Watery Diarrhea

Interventions

  • Oral rehydration solution (ORS)Drug

    For participants of oral arm, the study will use a standardized protocol that matches the same fluid volume calculated via the same formula but will be administered via oral or nasogastric routes. The study will use commercially available WHO recommended low osmolality ORS. The oral regimen follows the same sodium correction targets as the intravenous arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality from initiation of the intervention until hospital discharge among children under five years of age with hypernatremic dehydration associated with diarrhoea.Time frame: From enrollment to discharge (approximately 7 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Icddrb

    Dhaka, Dhaka Division, Bangladesh

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.